Can patients with advanced lymphoma take acalabrutinib?

Acalabrutinib (Acalabrutinib) is a BTK inhibitor, mainly used to treat B cell lymphoma, especially adults with chronic lymphocytic leukemia (CLL). In the treatment of advanced lymphoma, acotinib may be considered an effective treatment option.

For patients with advanced lymphoma, especially those who have had poor response to or intolerance to other treatments, acotinib may provide a new treatment avenue. It blocks the proliferation and survival of cancer cells by inhibiting abnormal signaling pathways inB cells, thereby inhibiting the development of lymphoma.

Clinical trial data show that acotinib has demonstrated significant efficacy in the treatment ofB cell lymphoma, including an increase in treatment response rate, improvement in survival data, and relatively mild side effects. These results provide support for acotinib as a potential treatment option in patients with advanced lymphoma.

When considering treatment with acotinib, however, physicians will consider a patient's specific circumstances, including factors such as overall health, other possible treatment options, and the patient's tolerance of treatment. Treatment decision-making is often an individualized process that requires adequate communication and shared decision-making between patient and physician.

Acotinib has been launched in China, but it has not yet been included in medical insurance. Since it has just been launched, it is still difficult for patients to purchase it domestically. They need to purchase acotinib through overseas channels. The cheaper ones abroad are mainly generic drugs, mainly Bangladeshi generic drugs. The price is around 6,000 to 7,000, and the ingredients of original drugs and generic drugs are basically the same.